ES2181165T3 - Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas. - Google Patents

Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.

Info

Publication number
ES2181165T3
ES2181165T3 ES98903122T ES98903122T ES2181165T3 ES 2181165 T3 ES2181165 T3 ES 2181165T3 ES 98903122 T ES98903122 T ES 98903122T ES 98903122 T ES98903122 T ES 98903122T ES 2181165 T3 ES2181165 T3 ES 2181165T3
Authority
ES
Spain
Prior art keywords
wound healing
latency
preparation
medicinal product
peptide associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98903122T
Other languages
English (en)
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of ES2181165T3 publication Critical patent/ES2181165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Uso de Péptido Asociado a Latencia o de un análogo peptídico del mismo que es capaz de mantener a un factor Transformador de Crecimiento 13 en un estado latente, para la fabricación de un medicamento para incrementar la velocidad de curación de heridas pero no para coadministración con factor Transformador de Crecimiento 13.
ES98903122T 1997-02-13 1998-02-13 Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas. Expired - Lifetime ES2181165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9702943.3A GB9702943D0 (en) 1997-02-13 1997-02-13 Wound healing

Publications (1)

Publication Number Publication Date
ES2181165T3 true ES2181165T3 (es) 2003-02-16

Family

ID=10807557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98903122T Expired - Lifetime ES2181165T3 (es) 1997-02-13 1998-02-13 Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.

Country Status (12)

Country Link
US (1) US6319907B1 (es)
EP (1) EP1009425B1 (es)
JP (1) JP4307561B2 (es)
AT (1) ATE223228T1 (es)
AU (1) AU728851B2 (es)
CA (1) CA2280873C (es)
DE (1) DE69807710T2 (es)
DK (1) DK1009425T3 (es)
ES (1) ES2181165T3 (es)
GB (1) GB9702943D0 (es)
PT (1) PT1009425E (es)
WO (1) WO1998035695A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756060B1 (en) * 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
AU2001268326A1 (en) * 2000-06-14 2001-12-24 Chanda Zaveri Peptides with physiological activity
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
JP2004536018A (ja) * 2000-07-31 2004-12-02 バル・イラン・ユニバーシティ 創傷治療のための方法および薬学的組成物
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
WO2005016254A2 (en) * 2003-07-16 2005-02-24 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
PL2205623T3 (pl) * 2007-10-29 2016-09-30 Ochronne tetrapeptydy do pielęgnacji skóry
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US20100172217A1 (en) * 2009-01-08 2010-07-08 Von Bezold Ernst System of Methods and Apparati for Handling and Modifying Information Energy and Matter by Formative Resonance
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US9387183B2 (en) 2011-12-28 2016-07-12 Kuwait University Method of treating diabetes-related impaired wound healing
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008291A2 (en) * 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
EP0968723B1 (en) 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor

Also Published As

Publication number Publication date
HK1025504A1 (en) 2000-11-17
CA2280873C (en) 2010-04-06
CA2280873A1 (en) 1998-08-20
EP1009425B1 (en) 2002-09-04
PT1009425E (pt) 2002-11-29
AU5995398A (en) 1998-09-08
JP2001511797A (ja) 2001-08-14
DE69807710T2 (de) 2003-06-05
DE69807710D1 (de) 2002-10-10
DK1009425T3 (da) 2002-10-14
WO1998035695A1 (en) 1998-08-20
JP4307561B2 (ja) 2009-08-05
GB9702943D0 (en) 1997-04-02
ATE223228T1 (de) 2002-09-15
EP1009425A1 (en) 2000-06-21
AU728851B2 (en) 2001-01-18
US6319907B1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2194308T3 (es) Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
MX9202436A (es) Composiciones para el cuidado del cabello y metodo para su preparacion.
BR9100843A (pt) Inalador e embalagem de medicamento para aplicacao com o mesmo
ES2160712T3 (es) Nueva preparacion farmaceutica para tratamiento del dolor.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
MY132705A (en) Novel compounds with analgesic effect
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
WO1992015605A3 (en) Inhibitors of human neutrophil elastase and human cathepsin g
SE9701161D0 (sv) New use I
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ITRM910002A0 (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
BR9815016A (pt) Utilização de uma mistura de um diol e um ácido alfa-hidroxi para o tratamento de doenças hiperceratóticas da pele
ES2064398T3 (es) Un nuevo antibiotico, mersacidina, un procedimiento para su preparacion y su utilizacion como medicamento.